drugset / Trial / NCT04976738

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

NCT04976738 ↗

Phase 1/2 Completed 28 enrolled Cymra Life Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.

Timeline

Start
2021-09-20
Primary completion
2022-06-15
Completion
2022-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cybis™ 10:25 Unknown 1.5 ml Other

Indications